

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 2007	2. REPORT TYPE Open Literature	3. DATES COVERED (From - To)		
4. TITLE AND SUBTITLE Direct detection of stereospecific soman hydrolysis by wild-type human Serum paraoxonase			5a. CONTRACT NUMBER	
			5b. GRANT NUMBER	
			5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yeung, DT, Smith, JR, Sweeney, RE, Lenz, DE, Cerasoli, DM			5d. PROJECT NUMBER	
			5e. TASK NUMBER	
			5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			8. PERFORMING ORGANIZATION REPORT NUMBER USAMRICD-P05-028	
US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDR-I 3100 Ricketts Point Road			Aberdeen Proving Ground, MD 21010-5400	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDZ-P 3100 Ricketts Point Road			10. SPONSOR/MONITOR'S ACRONYM(S)	
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
13. SUPPLEMENTARY NOTES Published in FEBS Journal, 274, 1183-1191, 2007.				
14. ABSTRACT See reprint.				
15. SUBJECT TERMS human serum paraoxonase (HuPON1), organophosphatase, paraoxonase, soman, VX, sarin, prophylaxis				
16. SECURITY CLASSIFICATION OF:		17. LIMITATION OF ABSTRACT UNLIMITED	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON Douglas M. Cerasoli
a. REPORT UNLIMITED	b. ABSTRACT UNLIMITED	c. THIS PAGE UNLIMITED		19b. TELEPHONE NUMBER (include area code) 410-436-1338

Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase

David T. Yeung^{1,2}, J. Richard Smith³, Richard E. Sweeney⁴, David E. Lenz¹ and Douglas M. Cerasoli¹

1 Physiology and Immunology Branch, Research Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA

2 Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore, MD, USA

3 Medical Diagnostic and Chemical Branch, Analytical Toxicology Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA

4 RESECO Research Engineering Consultants, Nottingham, PA, USA

Keywords

diisopropylfluorophosphate; GC/MS; paraoxonase 1; soman; stereoselectivity

Correspondence

D. Cerasoli, US Army Medical Research Institute of Chemical Defense, 3100 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5400, USA
Fax: +1 410 436 8377
Tel: +1 410 436 1338
E-mail: douglas.cerasoli@us.army.mil

(Received 19 October 2006, revised 5 December 2006, accepted 13 December 2006)

doi:10.1111/j.1742-4658.2006.05650.x

Human serum paraoxonase 1 (HuPON1; EC 3.1.8.1) is a calcium-dependent six-fold β -propeller enzyme that has been shown to hydrolyze an array of substrates, including organophosphorus (OP) chemical warfare nerve agents. Although recent efforts utilizing site-directed mutagenesis have demonstrated specific residues (such as Phe222 and His115) to be important in determining the specificity of OP substrate binding and hydrolysis, little effort has focused on the substrate stereospecificity of the enzyme; different stereoisomers of OPs can differ in their toxicity by several orders of magnitude. For example, the $C \pm P$ - isomers of the chemical warfare agent soman (GD) are known to be more toxic by three orders of magnitude. In this study, the catalytic activity of HuPON1 towards each of the four chiral isomers of GD was measured simultaneously via chiral GC/MS. The catalytic efficiency (k_{cat}/K_m) of the wild-type enzyme for the various stereoisomers was determined by a simultaneous solution of hydrolysis kinetics for each isomer. Derived k_{cat}/K_m values ranged from 625 to 4130 $\text{mM}^{-1} \cdot \text{min}^{-1}$, with isomers being hydrolyzed in the order of preference $C+P+ > C-P+ > C+P- > C-P-$. The results indicate that HuPON1 hydrolysis of GD is stereoselective; substrate stereospecificity should be considered in future efforts to enhance the OPase activity of this and other candidate bioscavenger enzymes.

Human serum paraoxonase 1 (HuPON1; EC 3.1.8.1) is a human plasma enzyme previously shown to hydrolyze insecticides and the highly toxic organophosphorus (OP) nerve agents sarin (GB), *O*-ethyl *S*-(2-diisopropylaminoethyl) methylphosphonothioate (VX), and soman (GD; pinacolyl methylphosphonofluoridate) *in vitro* and *in vivo* [1–3]. Although its catalytic efficacy against GB, VX, and GD is low, it is the capacity to hydrolyze these toxic nerve agents *in vivo* that makes HuPON1 attractive as a candidate bioscavenger of OP compounds. It has been theorized that a genetically

engineered variant of HuPON1 with at least a 10-fold increase in activity would be highly protective *in vivo* against intoxication by OP compounds [4–7].

GD is a member of a class of highly toxic acetylcholinesterase inhibitors, all of which have their leaving groups attached to a chiral phosphorus atom [8–11]. GD contains a second chiral center at one of the alkyl side chain carbon atoms. Therefore, it exists as four stereoisomers $C+P+$, $C+P-$, $C-P+$, and $C-P-$ (Fig. 1) [12–17]. Both of the P - isomers ($C \pm P$ -) are much more toxic *in vivo* and more readily inhibit

Abbreviations

DFP, diisopropylfluorophosphate; GB, sarin; GD, soman; HuPON1, human serum paraoxonase 1; OP, organophosphorus; PON1, paraoxonase 1; VX, *O*-ethyl *S*-(2-diisopropylaminoethyl) methylphosphonothioate.




Fig. 1. Stereoisomers of GD.

acetylcholinesterase *in vitro* than the P+ isomers; the bimolecular rate constants of acetylcholinesterase for the C±P+ isomers are ≈1000-fold lower than those of the C±P- isomers, with assumed correspondingly lower *in vivo* toxicity [12,13,15,18]. The hydrolytic cleavage of the phosphorus–fluorine (P–F) bond to form P–OH renders GD nontoxic; this reaction is catalyzed by OP hydrolases such as HuPON1 [3,9,18].

Although substantial efforts have focused on identifying amino acid residues essential for HuPON1 enzymatic activity [5,7,19–21], until very recently relatively little attention has been paid to the more subtle question of the substrate stereospecificity of the enzyme [22,23]. Knowledge of enzyme stereoselectivity is critical to understanding substrate orientation and for the rational design of mutants with enhanced activity towards the more toxic isomers of specific substrates, such as GD.

We studied the kinetics of HuPON1-catalyzed hydrolysis of the individual isomers of GD from a racemic mixture of the nerve agent at concentrations ranging from 0.2 to 3.0 mM, using a chiral GC/MS approach. This allowed for simultaneous determination of K_m , k_{cat} , and k_{cat}/K_m values of HuPON1 for each GD stereoisomer, resulting in unambiguous elucidation of the extent of stereoselectivity of HuPON1-mediated hydrolysis of GD.

Results

Analysis of GD stereoisomer hydrolysis using GC/MS

The decrease in the concentration of each of the GD isomers in the presence of HuPON1 over time was followed using GC/MS analysis. All four stereoisomers and the internal standard diisopropylfluorophosphate (DFP) were quantitatively separated (Fig. 2) using a Chiraldex γ -cyclodextrin trifluoroacetyl column [24]. The elution order of individual GD stereoisomers from a racemic sample was determined by examining the retention times of individual purified stereoisomers alone (data not shown).

The elution order detected was C-P-, C-P+, C+P-, and then C+P+ at approximately 12.0, 12.8, 13.2, and 13.6 min after injection, respectively (Fig. 2). Our elution order differs from those previously reported using different GC columns [9,16]. The DFP standard eluted after all four GD stereoisomers, at ≈17.3 min post injection. The clear separation of peaks in the elution profile allowed for the simultaneous determination of the fate of all four GD stereoisomers (Fig. 3) [9,12,25].

Spontaneous hydrolysis of GD stereoisomers

Hydrolytic assays were carried out in the absence of HuPON1 enzyme to define any effects of spontaneous hydrolysis at pH 7.4 at room temperature. The ratios of the areas under the curve for each stereoisomer were determined at 0.5, 1.0, 3.0, 5.0, 15.0, and 240 min following incubation of 2.0 mM racemic GD in supernatant from cells transfected with empty plasmid vector. The ratios of C-P-/C-P+/C+P-/C+P+ were identified relative to the DFP internal standard and were 23.4/26.7/26.6/23.2%, respectively, in good agreement with previous reports [26,27]. The absolute amount of GD and the relative percentages of each stereoisomer were consistent across all sampling times, differing by no more than 0.2% (data not shown), indicating negligible spontaneous hydrolysis.

Effects of GD stereoisomer racemization

Spontaneous racemization of GD stereoisomers is known to occur at the phosphorus atom in the presence of excess fluoride ion [26,27]. To determine if such racemization was occurring in our experimental system, studies were performed at room temperature in 50 mM glycine buffer (pH 7.4) with supernatant from cells transfected with empty plasmid vector. The extent




Fig. 2. Gas chromatographic separation of GD stereoisomers. Shown is a reconstructed ion chromatogram (m/z 126) of a 2.0 mM racemic sample of GD (no enzyme) analyzed by GC/MS after separation using a Chiraldex γ -cyclodextrin trifluoroacetyl column at 80 °C isothermal, with labels identifying peaks corresponding to the individual stereoisomers. The internal standard DFP eluted at \approx 17.3 min (not shown).




Fig. 3. Overlay of reconstructed ion chromatograms (m/z 126) of GD hydrolysis by HuPON1. Typical ion chromatograms indicating the relative abundance of the four GD stereoisomers (0.75 mM racemic GD) after different incubation periods (i.e. 0, 5.0, 15.0, and 120 min, as indicated) with wild-type HuPON1 enzyme. The various GD stereoisomers were eluted in the same order as shown in Fig. 2.

of racemization was studied in reactions containing semipurified 0.30 mM C-P-/C-P+ or C+P-/C+P+ mixtures of GD isomers in the presence of excess fluoride ions (which varied from 0 to 2.0 mM NaF). In addition, we incubated 1.0 mM racemic GD with 2.0 mM NaF under the same experimental conditions to determine the extent of racemization under those conditions. The results obtained from both sets of experiments indicated that under the conditions used, the presence of excess fluoride ions caused no appreciable racemization of either the C \pm P- or the C \pm P+

isomers. Furthermore, we did not observe any alteration in the GC/MS isomer elution profile after incubating 1.0 mM racemic GD with excess (2.0 mM NaF) fluoride ions.

Characterization of wild-type HuPON1 activity

Initial rates of enzymatic hydrolysis of the individual GD stereoisomers were estimated by plotting GD concentration (for the individual stereoisomers) as a function of time (Fig. 4). The concentration of each

specific stereoisomer was derived from a previously determined GD standard curve and the area under the curve for each stereoisomer was then normalized against the DFP internal standard. The kinetic parameter K_m of HuPON1 for each of the four stereoisomers of GD was determined from the derived kinetic model (Fig. 5, Table 1) as detailed in the Experimental procedures, and ranged from 0.27 to 0.91 mM in the following order: C-P- > C+P- > C+P+ > C-P+. The k_{cat} values for the hydrolysis of each stereoisomer were also determined from the derived model (Table 1); the values range from 501 to 1030 min⁻¹, where C+P+ > C-P+ > C+P- > C-P-. The bimolecular rate constants derived from the model ranged from 4130 to 625 mM⁻¹·min⁻¹ for C+P+ > C-P+ > C+P- > C-P-, respectively. The average K_m , k_{cat} , and k_{cat}/K_m values for all four GD stereoisomers in aggregate are 0.62 mM, 669 min⁻¹, and 1739 mM⁻¹·min⁻¹, which is in reasonable agreement with previously reported values obtained using a racemic mixture of GD and plasma derived HuPON1 in a different assay of enzymatic activity [1]. Finally, the kinetics of HuPON1-mediated GD hydrolysis (2 mM) determined in the presence of added NaF (1 mM) were indistinguishable from those measured in the absence of NaF; these results indicate that under the experimental conditions used, liberated fluoride ions do not enhance racemization of GD or influence the stereospecificity of HuPON1-mediated GD hydrolysis.




Fig. 4. Representative time-course of hydrolysis of 0.75 mM racemic GD by HuPON1. Stereoisomers of GD were separated as detailed in the Experimental procedures. Residual GD concentration at each time point was derived by comparison with a standard concentration curve. C-P- (■), C-P+ (▲), C+P- (▼), and C+P+ (◆). The curves were fitted by one-phase exponential decay ($r^2 = 0.97-0.98$). The plot shown is taken from one representative experiment.

Discussion

It has recently been reported that a gene-shuffled, bacterially expressed variant of PON1 exhibits *in vitro* stereospecificity for the less toxic isomers of both GD and cyclosarin [22]. In that study, enzymatic hydrolysis was determined by simultaneously measuring the amount of OP and the inhibitory capacity of the same OP after incubation with the hybrid PON1 enzyme for different time intervals [22]. Although that approach suggested preferential degradation of the less toxic isomers, the results could not distinguish between the C+ and C- isomers. Attempts to obtain K_m and k_{cat} values for the degradation of specific stereoisomers using this approach were unsuccessful [22].

In this study, we have demonstrated that recombinant wild-type HuPON1 exhibits modest, but distinct, stereoselectivity in its catalytic hydrolysis of the four GD stereoisomers. Whereas the C+P+ isomer was preferentially hydrolyzed by HuPON1 (Figs 3, 4; Table 1), the k_{cat} value for each of the C±P- isomers was similar to that for C-P+ and was only half that for the C+P+ isomer. Kinetic constants were determined directly for each stereoisomer after measuring the individual stereoisomer concentrations as a function of time. A critical assumption in the analytical model we developed to determine the kinetic constants of each stereoisomer is that each isomer behaves as an independent but competitive substrate in the reaction (see Supplementary material for a more detailed description of the model used).

Although our chromatographic technique obtained distinct baseline peak separation among the four GD stereoisomers (Fig. 2), it must be appreciated that the liberation of fluoride ions during hydrolysis has the potential to racemize the phosphorus chiral center of the unhydrolyzed GD in solution. Under conditions of excess fluoride ions, neither the enantiomeric nor racemic GD mixtures displayed observable differences in peak magnitude or elution order for the individual stereoisomers. Furthermore, the presence of added fluoride ions had no detectable effect on the stereoselectivity of HuPON1-mediated hydrolysis of GD, suggesting that fluoride-induced racemization at the phosphorus atom of GD does not contribute to the decrease in concentration of any particular stereoisomer. Rather, the results support the premise that each stereoisomer is behaving as an independent substrate competing for the same active site, as stipulated by our analytical model (Fig. 5). In addition, because HuPON1 was not purified in our experimental approach, the possibility also existed that other enzymes in the




Fig. 5. Reaction schematic of the racemic GD/HuPON1 system. A–D, various GD stereoisomers; E, PON1 enzyme; E_A–E_D, PON1–GD stereoisomer complexes; P–S, hydrolyzed products; k#, association/dissociation constants.

Table 1. Kinetic parameters for the enzymatic hydrolysis of the various GD stereoisomers by recombinant wild-type HuPON1. HuPON1 catalyzed GD hydrolysis was assayed in the presence of at least 1.0 mM CaCl₂ as described in Experimental procedures. Kinetic results presented for each isomer were determined from at least eight independent kinetic experiments (*n* = 8).

GD isomer	<i>K_m</i> (mM)	<i>k_{cat}</i> (min ⁻¹)	<i>k_{cat}/K_m</i> (mM ⁻¹ ·min ⁻¹)
C-P-	0.91 ± 0.34	501 ± 45	625 ± 241
C-P+	0.58 ± 0.23	593 ± 54	1160 ± 469
C+P-	0.71 ± 0.49	553 ± 163	1040 ± 465
C+P+	0.27 ± 0.08	1030 ± 94	4130 ± 1090

supernatant might be partially responsible for the observed hydrolysis of GD. However, supernatant collected from cells transfected with empty vector plasmids showed negligible GD hydrolysis, thus demonstrating that the observed hydrolysis of GD was mediated by only the HuPON1 enzyme.

The stereospecificity of several different enzymes for OP acetylcholinesterase inhibitors such as GD has been studied for several decades. To date, the enzymes examined have almost universally exhibited considerable stereospecific preference for the less toxic isomers of GD, including the recent results of Amitai *et al.* with a recombinant gene-shuffled version of PON1 [22,28]. Initial studies by Benschop *et al.* [12,25] showed that acetylcholinesterase was selectively inhibited by the C±P- GD stereoisomers by three orders of magnitude more rapidly than by the C±P+ isomers. Likewise, a bacterial phosphotriesterase [29] was found to hydrolyze the P+ GD analog diastereomers 1000-fold faster than the more toxic

P- isomers. Benschop *et al.* [25] and De Jong *et al.* [9] reported that for plasma and liver homogenates from guinea pigs, mice and marmosets, binding and/or hydrolysis of the C±P+ stereoisomers was preferred. The only previous report of a lack of stereospecificity in the enzyme-catalyzed hydrolysis of GD was a study by Little *et al.* [18] who reported that an enzyme with a molecular mass of 40 kDa, isolated as a single peak by HPLC from a rat liver homogenate, hydrolyzed all four GD stereoisomers at identical rates. The fact that PON1 is a liver-expressed serum enzyme with a molecular mass of 42 kDa and only modest stereoselectivity for GD suggests that PON1 may have been responsible for the majority of the enzymatic activity in that study. In this study, the detection of stereoselectivity against GD by HuPON1 may be the result of different sources of the enzyme (recombinant human versus rat plasma-derived) and/or improved instrumental resolution.

Akin to many OP hydrolases, HuPON1 has broad substrate specificity [3,7,19,20,22,30–34]. The recent publication of the crystal structure of a gene-shuffled, primarily rabbit PON1 variant [20] (the enzyme used in the report of Amitai *et al.* [22]) and of a DFPase-based HuPON1 homology model [5,7] have provided a framework to support the efforts currently underway to enhance PON1's enzymatic activity against OP substrates using rational design. This study demonstrates that the catalytic efficiency (*k_{cat}/K_m*) for hydrolysis of each of the GD stereoisomers by wild-type HuPON1 differs by less than one order of magnitude (Table 1). The *k_{cat}* values of the individual isomers are quite similar, with the turnover of the C+P+ isomer being

only twice that for the other three stereoisomers. The K_m values for the individual stereoisomers with wild-type HuPON1 show a wider (almost fourfold) variation, with the P- isomers exhibiting the highest values. This suggests that either the P- isomers of GD have a lower affinity for HuPON1 than the P+ isomers, or that the P- isomers form more stable enzyme–substrate complexes. Given the lack of information about the rate of enzyme/substrate to enzyme/product transitions in this system, it is not currently possible to distinguish between these nonmutually exclusive possibilities [35].

Data from HuPON1 presented in Table 1 suggest that the observed variations in catalytic efficiency for GD can be attributed largely to differences in the K_m values of the enzyme for the various stereoisomers. Although the stereochemistry of the substrates may be important for binding, the results suggest that once bound, the catalytic machinery is not overly sensitive to the chirality of the groups around the phosphorus atom. Therefore, small changes (via site-directed mutagenesis) that reduce the K_m for the more toxic isomers might be singularly sufficient to make the enzyme a viable bioscavenger for detoxification of OP anticholinesterase poisons *in vivo*. For example, a reduction in K_m by 10-fold with no change in the V_{max} value, would enhance catalytic turnover of the more toxic stereoisomers of GD such that they would be preferentially hydrolyzed by several fold [4,5,7]. Such a mutant would have considerable potential as a bioscavenger capable of providing protection against nerve agent poisoning.

Experimental procedures

Production of HuPON1

Wild-type recombinant HuPON1 enzymes were produced as described previously [7]. Briefly, a pcDNA3 plasmid (Invitrogen, Carlsbad, CA) encoding recombinant wild-type HuPON1 was transiently transfected into human 293T embryonic kidney cells, grown in DMEM (Cambrex Bioscience, Walkersville, MD) supplemented with 5% fetal bovine serum and 2% L-glutamine) at 70–90% confluence. Secreted HuPON1 protein in cultured supernatant was harvested seven days after transfection. HuPON1 expression was detected by immunoblotting with mouse anti-HuPON1 mAb (kindly provided by R. James, University Hospital of Geneva, Switzerland), probed with an alkaline-phosphatase conjugated rabbit anti-mouse serum, and quantitated by densitometry analysis (Un-Scan-It version 5.1, Silk Scientific Corp., Orem, UT) with a PON1 standard of known concentration (Randox Laboratories Ltd, Antrim, UK), and

verified by enzymatic assays for phenyl acetate and paraoxon hydrolysis [36–38].

Determination of GD hydrolysis

Racemic GD (2.0 mg·mL⁻¹ in saline), containing 2.5% diisopropyl carbodiimide added as a stabilizer, was obtained from the Research Development and Engineering Command (Aberdeen Proving Ground, MD). Analysis using nuclear magnetic resonance spectroscopy showed it to be 96.7% pure. The pure individual GD stereoisomers were previously prepared in ethyl acetate by the TNO Prins Maurits Laboratory (Rijswijk, the Netherlands) [12].

Somanase activity was determined at room temperature as detailed in Broomfield *et al.* [8] with minor variations. Specifically, GD hydrolysis experiments were carried out using 1.50 mL of supernatant from cells transfected with either the wild-type HuPON1 gene or empty vector. Supernatants were incubated with the indicated concentrations of GD in 50 mM glycine–NaOH buffer, pH 7.4 with 10 mM CaCl₂. Total reaction volume was 3.0 mL. At selected time intervals, 400 μ L aliquots were removed and inactivated through extraction with an equal volume of GC-grade ethyl acetate (EM Science, Cherry Hill, NJ) previously dried over a type 4A/grade 514 molecular sieve (Fisher Scientific, Fairlawn, NJ). The organic layer (containing unhydrolyzed GD) was then removed and dried over molecular sieve again. A 50- μ L sample of this dried sample was collected and spiked with DFP (Sigma-Aldrich, St Louis, MO) to a final concentration of 50 μ M as the internal standard before injection into the gas chromatograph [12]. The quantity of GD in each sample was determined by comparison with both the DFP internal standard present in each sample and a standard GD calibration curve. Calibration curves were obtained by using GD at five different concentrations also spiked with a final concentration of 50 μ M DFP in ethyl acetate as the internal standard. Kinetic parameters of GD hydrolysis were determined using at least eight different initial substrate concentrations that ranged from 0.2 to 3.0 mM.

To determine the elution/retention time profile of the four GD stereoisomers, samples of individual stereoisomers were run under the same conditions as those used to determine the calibration curve.

Excess fluoride/racemization control experiments

To determine whether racemization occurs in our experimental system, three independent control experiments were performed under the same conditions as those used to determine the calibration curve. First, 1.0 mM of racemic GD was incubated with culture medium from cells transfected with empty plasmid vector control in the presence of excess fluoride ions (2.0 mM NaF). Second, semipurified individual stereoisomers were also incubated with excessive

fluoride ions. Finally, wild-type HuPON1 was reacted with 2 mM GD as described above, but in the presence of 1 mM NaF.

GC/MS analysis

GC separation of the GD stereoisomers was performed using a modification of a previously developed method [24]. An Agilent 6890 gas chromatograph (Palo Alto, CA) was fitted with a 20 m \times 0.25 mm inside diameter Chiraldex γ -cyclodextrin trifluoroacetyl column, 0.125 μ m film thickness (Advanced Separation Technologies, Inc., Whippany, NJ). A 2.5 m \times 0.25 mm inside diameter cyano/phenyl/methyl deactivated fused silica retention gap (Chrompack, Inc., Raritan, NJ) was installed at the injection end of the GC and connected to the analytical column using a Chrompack deactivated Quick-Seal glass connector. Helium was used as the carrier gas at a linear velocity of 45 cm·s $^{-1}$. The oven temperature was held initially at 80 °C for 14 min, programmed from 80 to 90 °C at 5 °C·min $^{-1}$, and held at 90 °C for 3 min. Split injections of 1 μ L volume were made using an Agilent 7683 autosampler. The injection port temperature was 210 °C and the split ratio was \approx 1 : 100. The GC was interfaced to an Agilent 5973 mass spectrometer (MS) with an electron impact ion source. The MS operating conditions were as follows: ion source pressure \approx 1.0 \times 10 $^{-5}$ torr; source temperature, 230 °C; electron energy, 70 eV; electron multiplier voltage +200 V relative to the autotune setting; and transfer line temperature, 230 °C. The MS was operated using selected ion monitoring (SIM). Four ions (*m/z* 69, 82, 99 and 126) were monitored for the GD stereoisomers at a dwell time of 50 m·s $^{-1}$ for each ion resulting in a scan rate of 3.77 cycles·s $^{-1}$ [39]. Three ions (*m/z* 69, 101 and 127) were monitored for DFP [40]. A dwell time of 50 m·s $^{-1}$ for each ion resulted in a scan rate of 5 cycles·s $^{-1}$. The *m/z* 126 and 127 ions were used for quantitation of GD and DFP, respectively.

Calculation of kinetic constants

In the presence of a racemic mixture of GD, the catalyzed reaction is analogous to simultaneously deriving the kinetic constants for the hydrolysis of four competitive substrates. To do this, we used the model of GD–HuPON1 interaction shown in Fig. 5 and described in detail in the supplementary material. The first-order rate equations of the enzyme–substrate intermediates were set equal to zero (the enzyme ‘steady-state’ assumption). The resulting set of equations was solved to express the steady state enzyme–substrate intermediate levels as functions of the substrate concentrations and the kinetic parameters. A conservation of enzyme assumption was employed to obtain the free enzyme level in terms of the four enzyme–substrate intermediates. Using these relationships, each substrate rate equation was cast in terms of a single sub-

strate and integrated with respect to time to arrive at the solutions. The derived solution for all four of the substrates is shown below:

$$T_A = (A_0/V_{\max A})(1 - (A/A_0)(K_{mA}/K_{mA})(V_{\max A}/V_{\max A})) \\ + (B_0/V_{\max B})(1 - (A/A_0)(K_{mA}/K_{mB})(V_{\max B}/V_{\max A})) \\ + (C_0/V_{\max C})(1 - (A/A_0)(K_{mA}/K_{mC})(V_{\max C}/V_{\max A})) \\ + (D_0/V_{\max D})(1 - (A/A_0)(K_{mA}/K_{mD})(V_{\max D}/V_{\max A})) \\ (K_{mA}/V_{\max A}) \log_E(A/A_0)$$

$$T_B = (A_0/V_{\max A})(1 - (B/B_0)(K_{mB}/K_{mA})(V_{\max A}/V_{\max B})) \\ + (B_0/V_{\max B})(1 - (B/B_0)(K_{mB}/K_{mB})(V_{\max B}/V_{\max B})) \\ + (C_0/V_{\max C})(1 - (B/B_0)(K_{mB}/K_{mC})(V_{\max C}/V_{\max B})) \\ + (D_0/V_{\max D})(1 - (B/B_0)(K_{mB}/K_{mD})(V_{\max D}/V_{\max B})) \\ (K_{mB}/V_{\max B}) \log(B/B_0)$$

$$T_C = (A_0/V_{\max A})(1 - (C/C_0)(K_{mC}/K_{mA})(V_{\max A}/V_{\max C})) \\ + (B_0/V_{\max B})(1 - (C/C_0)(K_{mC}/K_{mB})(V_{\max B}/V_{\max C})) \\ + (C_0/V_{\max C})(1 - (C/C_0)(K_{mC}/K_{mC})(V_{\max C}/V_{\max C})) \\ + (D_0/V_{\max D})(1 - (C/C_0)(K_{mC}/K_{mD})(V_{\max D}/V_{\max C})) \\ (K_{mC}/V_{\max C}) \log(C/C_0)$$

$$T_D = (A_0/V_{\max A})(1 - (D/D_0)(K_{mD}/K_{mA})(V_{\max A}/V_{\max D})) \\ + (B_0/V_{\max B})(1 - (D/D_0)(K_{mD}/K_{mB})(V_{\max B}/V_{\max D})) \\ + (C_0/V_{\max C})(1 - (D/D_0)(K_{mD}/K_{mC})(V_{\max C}/V_{\max D})) \\ + (D_0/V_{\max D})(1 - (D/D_0)(K_{mD}/K_{mD})(V_{\max D}/V_{\max D})) \\ (K_{mD}/V_{\max D}) \log(D/D_0)$$

Where K_{mA} , K_{mB} , K_{mC} , and K_{mD} are the Michaelis–Menten constants for the four stereoisomers of GD; $V_{\max A}$, $V_{\max B}$, $V_{\max C}$, and $V_{\max D}$ are the corresponding maximum velocities; and A_0 , B_0 , C_0 , and D_0 are the initial concentrations of each stereoisomer.

Although complex, the solutions give the time it would take for each substrate (normalized to its initial level) to fall to a particular level. As such, they were used to graph curves of the substrate levels as functions of time. By adjusting the kinetic parameters we were able to use a Microsoft EXCEL 2003 spreadsheet to fit these model curves to the experimentally derived data (see Supplementary material). The bimolecular rate constants (k_{cat}/K_m) shown in Table 1 are the average of eight independent experiments \pm standard deviation ($n = 8$).

Acknowledgements

The work presented here by DTY is in partial fulfillment of the requirements for the Doctorate of Philosophy degree in Pharmacology from the University of Maryland, Baltimore, MD. This research was supported in part by an appointment to the Student Research Participation Program at the US Army Medical Research Institute of Chemical Defense administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US

Department of Energy and USAMRMC. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense.

References

- Broomfield CA, Morris BC, Anderson R, Josse D & Masson P (2000) Kinetics of nerve agent hydrolysis by a human plasma enzyme. *Proceedings of the CBMTS III conference*, 7–12 May 2000, Spiez, Switzerland.
- Fu AL, Wang YX & Sun MJ (2005) Naked DNA prevents soman intoxication. *Biochem Biophys Res Commun* **328**, 901–905.
- Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J & Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxy, soman and sarin. *Nat Genet* **14**, 334–336.
- Josse D, Lockridge O, Xie W, Bartels CF, Schopfer LM & Masson P (2001) The active site of human paraoxonase (PON1). *J Appl Toxicol* **21** (Suppl. 1), 7–11.
- Josse D, Broomfield CA, Cerasoli D, Kirby S, Nicholson J, Bahnsen B & Lenz DE (2002) Engineering of HuPON1 for use as a catalytic bioscavenger in organophosphate poisoning. *Proceedings of the US Army Medical Defense Bioscience Review*. US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD. DTIC no. pending.
- Watkins LM, Mahoney HJ, McCulloch JK & Raushel FM (1997) Augmented hydrolysis of diisopropyl fluorophosphate in engineered mutants of phosphotriesterase. *J Biol Chem* **272**, 25596–25601.
- Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnsen BJ, Lenz DE & Cerasoli DM (2004) Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. *Biochim Biophys Acta* **1702**, 67–77.
- Broomfield CA, Lenz DE & MacIver B (1986) The stability of soman and its stereoisomers in aqueous solution: toxicological considerations. *Arch Toxicol* **59**, 261–265.
- de Jong LP, van Dijk C & Benschop HP (1988) Hydrolysis of the four stereoisomers of soman catalyzed by liver homogenate and plasma from rat, guinea pig and marmoset, and by human plasma. *Biochem Pharmacol* **37**, 2939–2948.
- Sidell FR (1997) Nerve Agents. In *Medical Aspects of Chemical and Biological Warfare* (Zajtchuk R, ed.), pp. 129–179. Office of the Surgeon General at TMM Publication, Washington, DC.
- Benschop HP & de Jong LP (1998) Nerve agent stereoisomers: analysis, isolation, and toxicology. *Accounts Chem Res* **21**, 368–374.
- Benschop HP, Konings CA, van Genderen J & de Jong LP (1984) Isolation, anticholinesterase properties, and acute toxicity in mice of the four stereoisomers of the nerve agent soman. *Toxicol Appl Pharmacol* **72**, 61–74.
- Keijer JH & Wolring GZ (1969) Stereospecific aging of phosphonylated cholinesterases. *Biochim Biophys Acta* **185**, 465–468.
- Benschop HP (1975) The absolute configuration of chiral organophosphorus anticholinesterase poisoning. *Pesticide Biochem Physiol* **5**, 348–349.
- Benschop HP, Berends F & de Jong LP (1981) GLC-analysis and pharmacokinetics of the four stereoisomers of Soman. *Fundam Appl Toxicol* **1**, 177–182.
- Lenz DE, Little JS, Broomfield CA & Ray R (1990) Catalytic properties of nonspecific diisopropylfluorophosphatases. In *Chirality and Biological Activity* (Holmstedt B, Frank H & Testa B, eds), pp. 169–175. Alan R. Liss, New York, NY.
- Johnson JK, Cerasoli DM & Lenz DE (2005) Role of immunogen design in induction of soman-specific monoclonal antibodies. *Immunol Lett* **96**, 121–127.
- Little JS, Broomfield CA, Fox-Talbot MK, Boucher LJ, MacIver B & Lenz DE (1989) Partial characterization of an enzyme that hydrolyzes sarin, soman, tabun, and diisopropyl phosphorofluoridate (DFP). *Biochem Pharmacol* **38**, 23–29.
- Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I & Tawfik DS (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. *Proc Natl Acad Sci USA* **101**, 482–487.
- Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L et al. (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. *Nat Struct Mol Biol* **11**, 412–419.
- Josse D, Xie W, Renault F, Rochu D, Schopfer LM, Masson P & Lockridge O (1999) Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. *Biochemistry* **38**, 2816–2825.
- Amitai G, Gaidukov L, Adani R, Yishay S, Yacov G, Kushnir M, Teitboim S, Lindenbaum M, Bel P, Khersonsky O et al. (2006) Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. *FEBS J* **273**, 1906–1919.
- Khersonsky O & Tawfik DS (2006) The histidine 115–histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. *J Biol Chem* **281**, 7649–7656.
- Smith JR & Schlager JJ (1996) Gas chromatographic separation of the stereoisomers of organophosphorus chemical warfare agents using cyclodextrin capillary columns. *J High Resolution Chromatogr* **19**, 151–154.

25 Benschop HP, Konings CA, van Genderen J & de Jong LP (1984) Isolation, *in vitro* activity, and acute toxicity in mice of the four stereoisomers of soman. *Fundam Appl Toxicol* **4**, S84–S95.

26 Benschop HP, Bijleveld EC, Otto MF, Degenhardt CE, Van Helden HP & de Jong LP (1985) Stabilization and gas chromatographic analysis of the four stereoisomers of 1,2,2-trimethylpropyl methylphosphonofluoridate (soman) in rat blood. *Anal Biochem* **151**, 242–253.

27 de Jong LP, Bijleveld EC, van Dijk C & Benschop HP (1987) Assay of the chiral organophosphate, soman, in biological samples. *Int J Environ Anal Chem* **29**, 179–197.

28 Harvey SP, Kolakowski JE, Cheng TC, Rastogi VK, Reiff LP, DeFrank JJ, Raushel FM & Hill C (2005) Stereospecificity in the enzymatic hydrolysis of cyclosarin (GF). *Enzyme Microbial Technol* **37**, 547–555.

29 Li W, Lum KT, Chen-Goodspeed M, Sogorb MA & Raushel FM (2001) Stereoselective detoxification of chiral sarin and soman analogues by phosphotriesterase. *Bioorg Med Chem* **9**, 2083–2091.

30 Lacinski M, Skorupski W, Cieslinski A, Sokolowska J, Trzeciak WH & Jakubowski H (2004) Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. *Cell Mol Biol (Noisy-le-Grand)* **50**, 885–893.

31 Primo-Parmo SL, Sorenson RC, Teiber J & Du La BN (1996) The human serum paraoxonase/arylesterase gene (*PON1*) is one member of a multigene family. *Genomics* **33**, 498–507.

32 Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O & Du La BN (1995) Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. *Proc Natl Acad Sci USA* **92**, 7187–7191.

33 Rodrigo L, Mackness B, Durrington PN, Hernandez A & Mackness MI (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. *Biochem J* **354**, 1–7.

34 Aharoni A, Gaidukov L, Khersonsky OM, QGS, Roodveldt C & Tawfik DS (2005) The ‘evolvability’ of promiscuous protein functions. *Nat Genet* **37**, 73–76.

35 Tipton KF (1973) Enzyme kinetics in relation to enzyme inhibitors. *Biochem Pharmacol* **22**, 2933–2941.

36 Gan KN, Smolen A, Eckerson HW & Du La BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. *Drug Metab Dispos* **19**, 100–106.

37 Yeung DT, Lenz DE & Cerasoli DM (2005) Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. *FEBS J* **272**, 2225–2230.

38 Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C & Du La B (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. *Arterioscler Thromb Vasc Biol* **18**, 1617–1624.

39 Wils ERJ (2005) Gas chromatography/mass spectrometry in analysis of chemicals related to the chemical weapons convention. In *Chemical Weapons Convention Chemical Analysis* (Mesilaakso, M, ed.), pp. 249–279. John Wiley, Hoboken.

40 Enqvist J, Manninen A, Ravid P, Kokko M, Kuronen P, Hesso A, Savolaihti P, Ali-Mattila E, Kenttamaa H, Rautio M *et al.* (1983) Identification of precursors of warfare agents, degradation products of non-phosphorus agents, and some potential agents. In *Systematic Identification of Chemical Warfare Agents* (Miettinen JK, Hase T, Hirsjärvi P, Paasivirta J, Pyysalo H & Rahkamaa E, eds). The Ministry for Foreign Affairs of Finland, Helsinki.

Supplementary material

The following supplementary material is available online:

Fig. S1. Reaction schematic of the racemic GD HuPON1 system.

Fig. S2. Hydrolysis of 0.37 mM racemic GD by HuPON1.

Fig. S3. Comparison of theoretical and numerical solutions.

Fig. S4. Comparison of assumed enzyme ‘steady-state’ levels and actual (numerically integrated) levels.

Fig. S5. Lineweaver–Burke plot of theoretical solutions and measured data for hydrolysis of 1.67 mM racemic GD by HuPON1.

Fig. S6. Hanes–Woolf plot of theoretical solutions and measured data for hydrolysis of 1.67 mM racemic GD by HuPON1.

Fig. S7. Eadie–Hofstee plot of theoretical solutions and measured data for hydrolysis of 1.67 mM racemic GD by HuPON1.

This material is available as part of the online article from <http://www.blackwell-synergy.com>

Please note: Blackwell Publishing is not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.